QCM
VKTX icon

Qsemble Capital Management’s Viking Therapeutics VKTX Stock Holding History

Qsemble Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Sell
47,971
-32,307
-40% -$1.04M 0.24% 155
2026
Q1 		$2.61M Buy
80,278
+44,857
+127% +$1.44M 0.2% 170
2025
Q4 		$1.25M Sell
35,421
-35,731
-50% -$1.27M 0.1% 247
2025
Q3 		$1.87M Buy
71,152
+44,847
+170% +$1.34M 0.18% 172
2025
Q2 		$697K Buy
26,305
+12,368
+89% +$326K 0.07% 293
2025
Q1 		$337K Buy
+13,937
New +$440K 0.04% 347

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Qsemble Capital Management's VKTX Position: Q2 2026 in Review

Qsemble Capital Management reduced its Viking Therapeutics (VKTX) stake by 40% in Q2 2026, selling an estimated $1.04M and leaving 47,971 shares worth $1.87M. The position accounts for 0.24% of the portfolio, ranked #155.

Qsemble Capital Management first reported a position in VKTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.61M in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Qsemble Capital Management held 47,971 shares of Viking Therapeutics worth $1.87M as of Q2 2026.
  • Qsemble Capital Management sold 32,307 Viking Therapeutics shares in Q2 2026, an estimated $1.04M.
  • Viking Therapeutics made up 0.24% of Qsemble Capital Management's portfolio in Q2 2026, its #155 holding.
  • Qsemble Capital Management first reported a position in Viking Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Qsemble Capital Management's Viking Therapeutics position peaked at $2.61M in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Qsemble Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.